文献速递糖尿病

儿童糖尿病诊断时胰岛自身抗体阴性且血糖轻度升高应检测MODY:瑞典5年全国儿科队列研究启示

Absence of Islet Autoantibodies and Modestly Raised Glucose Values at Diabetes Diagnosis Should Lead to Testing for MODY: Lessons From a 5-Year Pediatric Swedish National Cohort Study.
PubMed 文献 · Diabetes Care · 2019-11-08

该研究基于瑞典全国前瞻性儿科队列(n=3,933,1-18岁,2005年5月至2010年12月诊断糖尿病),分析GCK、HNF1A和HNF4A MODY在诊断时的鉴别特征。MODY最低患病率为1.2%;四种胰岛自身抗体全阴性、HbA1c较低、血糖较低、父母糖尿病史和無DKA是MODY的鉴别因素。在303例自身抗体阴性患者中检测出46例MODY(检出率15%),而限定于73例自身抗体阴性且HbA1c<7.5%者检出36/46例(78%,检出率49%)。结论:儿科糖尿病诊断时,若所有胰岛自身抗体阴性且HbA1c<7.5%,应进行GCK、HNF1A和HNF4A MODY检测。

要点

  • 儿童糖尿病诊断时,四种胰岛自身抗体全阴性且HbA1c<7.5%应检测MODY。
  • MODY最低患病率1.2%,自身抗体阴性者中检出率15%。
  • 限定HbA1c<7.5%的自身抗体阴性者检出率49%,可识别78%的MODY。

核心结论

  • 儿科糖尿病诊断时,所有胰岛自身抗体阴性且HbA1c<7.5%(58 mmol/mol)应检测GCK、HNF1A和HNF4A MODY。
  • 检测所有四种胰岛自身抗体阴性的12%患者可有效避免漏诊MODY,但检出率较低。
  • 识别MODY可实现长期良好血糖控制且无需胰岛素治疗。

研究设计与样本

  • 瑞典全国前瞻性队列Better Diabetes Diagnosis,纳入2005年5月至2010年12月诊断糖尿病的1-18岁患者n=3,933。
  • 诊断时收集临床数据、胰岛自身抗体(GAD、IA-2、ZnT8和IAA)、HLA分型和C肽。
  • 通过常规临床或研究检测对GCK、HNF1A和HNF4A测序以识别MODY。

主要发现

  • MODY最低患病率为1.2%。
  • MODY鉴别因素:四种胰岛自身抗体全阴性(100% vs. 11%非已知MODY;P=2×10-44)。
  • MODY鉴别因素:HbA1c(7.0% vs. 10.7% [53 vs. 93 mmol/mol];P=1×10-20)。
  • MODY鉴别因素:血浆葡萄糖(11.7 vs. 26.7 mmol/L;P=3×10-19)、父母糖尿病(63% vs. 12%;P=1×10-15)、DKA(0% vs. 15%;P=0.001)。
  • 检测303例自身抗体阴性患者识别46例MODY(检出率15%);限定于73例自身抗体阴性且HbA1c<7.5%(58 mmol/mol)者识别36/46例(78%)MODY(检出率49%);随访时46例MODY HbA1c为6.4%(47 mmol/mol),42/46(91%)未使用胰岛素。

关键数值与推荐

  • 儿科糖尿病诊断时,所有胰岛自身抗体阴性且HbA1c<7.5%(58 mmol/mol)应进行GCK、HNF1A和HNF4A MODY检测。
  • 检测所有四种胰岛自身抗体阴性的12%患者是有效策略,但检出率较低。

临床怎么用

  • 儿科糖尿病诊断时,应检测四种胰岛自身抗体,若全阴性且HbA1c<7.5%则启动MODY基因检测。
  • 识别MODY可避免不必要的胰岛素治疗,实现长期良好血糖控制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Identifying maturity-onset diabetes of the young (MODY) in pediatric populations close to diabetes diagnosis is difficult. Misdiagnosis and unnecessary insulin treatment are common. We aimed to identify the discriminatory clinical features at diabetes diagnosis of patients with glucokinase (GCK), hepatocyte nuclear factor-1A (HNF1A), and HNF4A MODY in the pediatric population. RESEARCH DESIGN AND METHODS: Swedish patients (n = 3,933) aged 1-18 years, diagnosed with diabetes May 2005 to December 2010, were recruited from the national consecutive prospective cohort Better Diabetes Diagnosis. Clinical data, islet autoantibodies (GAD insulinoma antigen-2, zinc transporter 8, and insulin autoantibodies), HLA type, and C-peptide were collected at diagnosis. MODY was identified by sequencing GCK, HNF1A, and HNF4A, through either routine clinical or research testing. RESULTS: The minimal prevalence of MODY was 1.2%. Discriminatory factors for MODY at diagnosis included four islet autoantibody negativity (100% vs. 11% not-known MODY; P = 2 × 10-44), HbA1c (7.0% vs. 10.7% [53 vs. 93 mmol/mol]; P = 1 × 10-20), plasma glucose (11.7 vs. 26.7 mmol/L; P = 3 × 10-19), parental diabetes (63% vs. 12%; P = 1 × 10-15), and diabetic ketoacidosis (0% vs. 15%; P = 0.001). Testing 303 autoantibody-negative patients identified 46 patients with MODY (detection rate 15%). Limiting testing to the 73 islet autoantibody-negative patients with HbA1c <7.5% (58 mmol/mol) at diagnosis identified 36 out of 46 (78%) patients with MODY (detection rate 49%). On follow-up, the 46 patients with MODY had excellent glycemic control, with an HbA1c of 6.4% (47 mmol/mol), with 42 out of 46 (91%) patients not on insulin treatment. CONCLUSIONS: At diagnosis of pediatric diabetes, absence of all islet autoantibodies and modest hyperglycemia (HbA1c <7.5% [58 mmol/mol]) should result in testing for GCK, HNF1A, and HNF4A MODY. Testing all 12% patients negative for four islet autoantibodies is an effective strategy for not missing MODY but will result in a lower detection rate. Identifying MODY results in excellent long-term glycemic control without insulin.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Carlsson A, Shepherd M, Ellard S, et al. Absence of Islet Autoantibodies and Modestly Raised Glucose Values at Diabetes Diagnosis Should Lead to Testing for MODY: Lessons From a 5-Year Pediatric Swedish National Cohort Study. Diabetes Care. 2019. PMID: 31704690. doi:10.2337/dc19-0747

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。